Nephrocare Health IPO opens; should you apply? Market guru Anil Singhvi decodes

IndiGo under SEBI radar for THIS reason; check share price update

Fresh Turbulence for IndiGo: CCI and Parliamentary panel tighten scrutiny, 10% flight cut ordered

Meesho Share Price: E-commerce stock surges 45% on debut on NSE, BSE – Buy, sell or hold? Anil Singhvi weighs in

Vidya Wires share price opens at Rs 52 on NSE, BSE—Massive subscription, muted listing

Aequs enters listed space at 13% premium; here's what Anil Singhvi suggests

Slight relief in Delhi’s air quality, yet pollution and cold hold firm

India-US trade talks set to resume on Wednesday, first since Trump 2.0 exited record shutdown

Gold & Silver Price Today: MCX outlook with key levels, trading strategy and fresh targets for traders

Stock Market Today: Sensex begins flat, Nifty tests 25,900; IndiGo, JSW Steel top losers

The Indian pharmaceutical sector is expected to achieve 7-9 per cent revenue growth in FY 2026, driven by strong domestic and European demand, despite a significant slowdown in its US market, a report said on Thursday.&nbsp;

Indian pharma companies' revenue to grow 7-9% in FY26 amidst US market risks: Report

Pharmaceutical major Pfizer has been issued a warning letter by US FDA on issues of failed sterility test, Environmental Monitoring Program and data integrity remediation issues; Warning letter was issued on 25 March, against the Vishakhapattanam plant of the company

Setback for Pfizer, US FDA issues warning letter to company's Vizag plant

Sachin Menon, Partner and Head, Indirect tax at KPMG India said, " With the passage of the bill in Rajya Sabha, the action will now shift to the corporate world. Due to the uncertainty on the fate of GST, many of the companies remain unprepared for the implementation of GST. "

GST Bill: How will it impact realty, consumer goods, auto, pharma

The buzz words in the document are creativity and innovation. The policy has seven broad objectives and offers a range of prescriptions. The first objective is “IPR awareness, outreach and promotion” as a key goal is to get India to generate more IPR.

Will India’s new IPR policy put a lid on the polarising discourse on pharma and patents? 

After its failure to acquire Allergan, Pfizer recently announced plans to buy Anacor Pharmaceuticals